Idenix Pharmaceuticals Inc. (IDIX)
-NasdaqGS 4.19 
0.04(0.96%) 4:00PM EDT|After Hours
:
4.13 0.06 (1.50%) 4:13PM EDT
| Prev Close: | 4.15 |
|---|
| Open: | 4.05 |
|---|
| Bid: | 4.18 x 7000 |
|---|
| Ask: | 4.19 x 14800 |
|---|
| 1y Target Est: | 5.64 |
|---|
| Beta: | 0.35 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 3.86 - 4.24 |
|---|
| 52wk Range: | 3.21 - 11.30 |
|---|
| Volume: | 1,047,507 |
|---|
| Avg Vol (3m): | 887,092 |
|---|
| Market Cap: | 561.29M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.60 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Idenix Pharmaceuticals' CEO Presents at UBS Global Healthcare Services Conference (Transcript)at Seeking Alpha(Tue, May 21)
- Idenix Pharmaceuticals' CEO Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)at Seeking Alpha(Wed, May 15)
- Seth Klarman's Worst Performing Stock Picks Year-To-Dateat Seeking Alpha(Mon, May 13)
- Idenix Pharmaceuticals to Present at Three Upcoming Healthcare ConferencesGlobeNewswire(Wed, May 8)
- IDENIX PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Sat, May 4)
- Gilead Misses Analysts’ Estimates on Sales of HIV Drugsat Bloomberg(Thu, May 2)
- Idenix Pharmaceuticals Reports First Quarter 2013 Financial ResultsGlobeNewswire(Tue, Apr 30)
- IDENIX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, Apr 30)
- IDENIX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Tue, Apr 30)
- FDA Approvals Accelerate and Opportunities Arise in Hepatitis C Market: A Wall Street Transcript Interview with Brian Skorney, Senior Analyst at Robert W. Baird & Co.Wall Street Transcript(Mon, Apr 29)
- Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL MeetingGlobeNewswire(Wed, Apr 24)
- 3 Small Biotechs Top Hedge Funds Are Investing Inat Motley Fool(Tue, Apr 23)
- Achillion: Moving Beyond Sofosbuvir's Shadowat Seeking Alpha(Tue, Apr 16)
- Should You Sell These Biotechnology Stocksat Motley Fool(Mon, Apr 15)
- Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL)GlobeNewswire(Mon, Apr 8)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 15.94 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.89 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.23 |
|---|
| Mean Recommendation*: | 2.6 |
|---|
| PEG Ratio (5 yr expected): | 0.04 |
|---|
Business Summary
Idenix Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of drugs for the treatment of human viral diseases in the United States and France.
View More